| 產(chǎn)品編號(hào) | D51559 |
| 英文名稱 | Riamilovir sodium hydrate |
| 中文名稱 | |
| 別 名 | Influenza virus抑制劑 |
| 克 隆 號(hào) | |
| CAS | 928659-17-0 |
| 理論分子量 | 310.2 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Lyophilized |
| 保存條件 | Store in dry, dark place for one year. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產(chǎn)品介紹 |
Riamilovir, also known as Triazavirin, is an antiviral drug candidate. Tiazavirin is a broad-spectrum antiviral drug developed in Russia. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2. |
